Abbott to Pay $385 Million to End US Claims Over Infant Formula

Abbott Laboratories has agreed to pay $385 million to settle U.S. allegations related to poor manufacturing practices at two facilities, including one involving an investigation of a contaminated facility that made powder infant formula. The settlement resolves claims that the company violated federal regulations in the production of infant formula, which is a critical product for the health and well-being of infants. The U.S. Food and Drug Administration (FDA) had previously raised concerns about the manufacturing practices at Abbott's facilities, prompting an investigation into the company's operations. The settlement amount of $385 million reflects the seriousness of the allegations and the need for Abbott to address the issues raised by the FDA. According to a report by Claims Journal, the settlement will allow Abbott to put this issue behind it and focus on ensuring the safety and quality of its products. The company has stated that it is committed to meeting the highest standards of quality and compliance in its manufacturing processes. This settlement is a significant development for Abbott Laboratories, a global healthcare company that produces a wide range of medical devices, diagnostics, and nutritional products. The company's reputation and financial standing could be impacted by the outcome of this settlement, as well as any ongoing regulatory scrutiny. Experts in the healthcare and regulatory fields have noted that settlements like this highlight the importance of companies adhering to strict manufacturing standards, especially when it comes to products that are essential for public health. The FDA plays a crucial role in ensuring the safety and efficacy of medical products, and companies must comply with regulations to maintain consumer trust and confidence. The financial impact of the $385 million settlement on Abbott Laboratories remains to be seen, but the company's stock price could be affected by the news. Investors and analysts will be closely monitoring the situation to assess the long-term implications for Abbott's business operations and financial performance. In conclusion, the settlement between Abbott Laboratories and the U.S. government over allegations related to infant formula manufacturing practices underscores the importance of regulatory compliance and product safety in the healthcare industry. Companies must prioritize quality control and adherence to regulations to protect consumers and maintain their reputation in the market. **Ticker symbols:** - Abbott Laboratories: ABT **Sources:** - [Claims Journal](https://www.claimsjournal.com/news/national/2026/09/15/340149.htm) Social Commentary influenced the creation of this article.